Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma

Leukemia volume 21, pages 780–787 (2007)Cite this article

Abstract

Mediastinal large B-cell (MBL) and classical Hodgkin lymphoma (HL) have several pathogenic mechanisms in common. As we recently observed aberrant tyrosine kinase (TK) activities in HL, we now analysed also MBL for such activities. Indeed, MBL and HL were the only B-cell lymphomas where elevated cellular phospho-tyrosine contents were typical features. Three TKs, JAK2, RON and TIE1, not expressed in normal B cells, were each expressed in about 30% of MBL cases, and 75% of cases expressed at least one of the TKs. Among the intracellular pathways frequently triggered by TKs, the PI3K/AKT pathway was activated in about 40% of MBLs and essential for survival of MBL cell lines, whereas the RAF/mitogen-activated protein kinase pathway seemed to be inhibited. No activating mutations were detected in the three TKs in MBL cell lines and primary cases. RON and TIE1 were each also expressed in about 35% and JAK2 in about 53% of HL cases. JAK2 genomic gains are frequent in MBL and HL but we observed no strict correlation of JAK2 genomic status with JAK2 protein expression. In conclusion, aberrant TK activities are a further shared pathogenic mechanism of MBL and HL and may be interesting targets for therapeutic intervention.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

Article 15 December 2022

Cristina López, Birgit Burkhardt, … Reiner Siebert

References

  1. Banks PM, Warnke RA (eds). Mediastinal (thymic) large B-cell lymphoma. IARC Press: Lyon, 2001.

    Google Scholar 

  2. Barth TF, Leithäuser F, Joos S, Bentz M, Möller P . Mediastinal (thymic) large B-cell lymphoma: where do we stand? Lancet Oncol 2002; 3: 229–234.

    Article  Google Scholar 

  3. Kanavaros P, Gaulard P, Charlotte F, Martin N, Ducos C, Lebezu M et al. Discordant expression of immunoglobulin and its associated molecule mb-1/CD79a is frequently found in mediastinal large B cell lymphomas. Am J Pathol 1995; 146: 735–741.

    CAS  Google Scholar 

  4. Leithäuser F, Bäuerle M, Huynh MQ, Möller P . Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma. Blood 2001; 98: 2762–2770.

    Article  Google Scholar 

  5. Ritz O, Leithäuser F, Hasel C, Brüderlein S, Ushmorov A, Möller P et al. Downregulation of internal enhancer activity contributes to abnormally low immunoglobulin expression in the MedB-1 mediastinal B-cell lymphoma cell line. J Pathol 2005; 205: 336–348.

    Article  CAS  Google Scholar 

  6. Möller P, Moldenhauer G, Momburg F, Lämmler B, Eberlein-Gonska M, Kiesel S et al. Mediastinal lymphoma of clear cell type is a tumor corresponding to terminal steps of B cell differentiation. Blood 1987; 69: 1087–1095.

    Google Scholar 

  7. Copie-Bergman C, Gaulard P, Maouche-Chretien L, Briere J, Haioun C, Alonso MA et al. The MAL gene is expressed in primary mediastinal large B-cell lymphoma. Blood 1999; 94: 3567–3575.

    CAS  Google Scholar 

  8. Poppema S, Kluiver JL, Atayar C, Berg A, Rosenwald A, Hummel M et al. Report: workshop on mediastinal grey zone lymphoma. Eur J Haematol 2005; 75 (Suppl 66): 45–52.

    Article  Google Scholar 

  9. Bentz M, Barth TF, Brüderlein S, Bock D, Schwerer MJ, Baudis M et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer 2001; 30: 393–401.

    Article  CAS  Google Scholar 

  10. Joos S, Küpper M, Ohl S, von Bonin F, Mechtersheimer G, Bentz M et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 2000; 60: 549–552.

    CAS  Google Scholar 

  11. Joos S, Menz CK, Wrobel G, Siebert R, Gesk S, Ohl S et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood 2002; 99: 1381–1387.

    Article  CAS  Google Scholar 

  12. Joos S, Granzow M, Holtgreve-Grez H, Siebert R, Harder L, Martin-Subero JI et al. Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int J Cancer 2003; 103: 489–495.

    Article  CAS  Google Scholar 

  13. Martin-Subero JI, Gesk S, Harder L, Sonoki T, Tucker PW, Schlegelberger B et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood 2002; 99: 1474–1477.

    Article  CAS  Google Scholar 

  14. Martin-Subero JI, Knippschild U, Harder L, Barth TF, Riemke J, Grohmann S et al. Segmental chromosomal aberrations and centrosome amplifications: pathogenetic mechanisms in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma? Leukemia 2003; 17: 2214–2219.

    Article  CAS  Google Scholar 

  15. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100: 2961–2969.

    Article  CAS  Google Scholar 

  16. Feuerhake F, Kutok JL, Monti S, Chen W, Lacasce AS, Cattoretti G et al. NF kappa B activity, function and target gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005; 106: 1392–1399.

    Article  CAS  Google Scholar 

  17. Jungnickel B, Staratschek-Jox A, Bräuninger A, Spieker T, Wolf J, Diehl V et al. Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 2000; 191: 395–402.

    Article  CAS  Google Scholar 

  18. Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, Kapp U et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2002; 99: 618–626.

    Article  CAS  Google Scholar 

  19. Guiter C, Dusanter-Fourt I, Copie-Bergman C, Boulland ML, Le Gouvello S, Gaulard P et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood 2004; 104: 543–549.

    Article  CAS  Google Scholar 

  20. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851–862.

    Article  CAS  Google Scholar 

  21. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871–3879.

    Article  CAS  Google Scholar 

  22. Renné C, Willenbrock K, Küppers R, Hansmann ML, Bräuninger A . Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. Blood 2005; 105: 4051–4059.

    Article  Google Scholar 

  23. Nacheva E, Dyer MJ, Metivier C, Jadayel D, Stranks G, Morilla R et al. B-cell non-Hodgkin's lymphoma cell line (Karpas 1106) with complex translocation involving 18q21.3 but lacking BCL2 rearrangement and expression. Blood 1994; 84: 3422–3428.

    CAS  Google Scholar 

  24. Möller P, Brüderlein S, Sträter J, Leithäuser F, Hasel C, Bataille F et al. MedB-1, a human tumor cell line derived from a primary mediastinal large B-cell lymphoma. Int J Cancer 2001; 92: 348–353.

    Article  Google Scholar 

  25. Eisen MB, Spellman PT, Brown PO, Botstein D . Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863–14868.

    Article  CAS  Google Scholar 

  26. Martin-Subero JI, Harder L, Gesk S, Schlegelberger B, Grote W, Martinez-Climent JA et al. Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. Int J Cancer 2002; 98: 470–474.

    Article  CAS  Google Scholar 

  27. Pulford K, Delsol G, Roncador G, Biddolph S, Jones M, Mason DY . Immunohistochemical screening for oncogenic tyrosine kinase activation. J Pathol 1999; 187: 588–593.

    Article  CAS  Google Scholar 

  28. Schlessinger J . Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211–225.

    Article  CAS  Google Scholar 

  29. Danilkovitch A, Donley S, Skeel A, Leonard EJ . Two independent signaling pathways mediate the antiapoptotic action of macrophage-stimulating protein on epithelial cells. Mol Cell Biol 2000; 20: 2218–2227.

    Article  CAS  Google Scholar 

  30. Kontos CD, Cha EH, York JD, Peters KG . The endothelial receptor tyrosine kinase Tie1 activates phosphatidylinositol 3-kinase and Akt to inhibit apoptosis. Mol Cell Biol 2002; 22: 1704–1713.

    Article  CAS  Google Scholar 

  31. Rommel C, Clarke BA, Zimmermann S, Nunez L, Rossman R, Reid K et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 1999; 286: 1738–1741.

    Article  CAS  Google Scholar 

  32. Zimmermann S, Moelling K . Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999; 286: 1741–1744.

    Article  CAS  Google Scholar 

  33. Dutton A, Reynolds GM, Dawson CW, Young LS, Murray PG . Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol 2005; 205: 498–506.

    Article  CAS  Google Scholar 

  34. Uddin S, Hussain A, Al-Hussein K, Platanias LC, Bhatia KG . Inhibition of phosphatidylinositol 3′-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochem Biophys Res Commun 2004; 320: 932–938.

    Article  CAS  Google Scholar 

  35. Melzner I, Bucur AJ, Brüderlein S, Dorsch K, Hasel C, Barth TF et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 2005; 105: 2535–2542.

    Article  CAS  Google Scholar 

  36. Melzner I, Weniger MA, Bucur AJ, Brüderlein S, Dorsch K, Hasel C et al. Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. Int J Cancer 2006; 118: 1941–1944.

    Article  CAS  Google Scholar 

  37. Zhou YQ, He C, Chen YQ, Wang D, Wang MH . Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene 2003; 22: 186–197.

    Article  CAS  Google Scholar 

  38. Frohling S, Scholl C, Gilliland DG, Levine RL . Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005; 23: 6285–6295.

    Article  CAS  Google Scholar 

  39. Melzner I, Weniger MA, Menz CK, Möller P . Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Leukemia 2005; 20: 157–158.

    Article  Google Scholar 

  40. Vikkula M, Boon LM, Carraway III KL, Calvert JT, Diamonti AJ, Goumnerov B et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996; 87: 1181–1190.

    Article  CAS  Google Scholar 

  41. Santoro MM, Penengo L, Minetto M, Orecchia S, Cilli M, Gaudino G . Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor. Oncogene 1998; 17: 741–749.

    Article  CAS  Google Scholar 

  42. Mandell JW . Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol 2003; 163: 1687–1698.

    Article  CAS  Google Scholar 

  43. Mestre C, Rubio-Moscardo F, Rosenwald A, Climent J, Dyer MJ, Staudt L et al. Homozygous deletion of SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays. Leukemia 2005; 19: 1082–1084.

    Article  CAS  Google Scholar 

  44. Haralambieva E, Jones M, Roncador GM, Cerroni L, Lamant L, Ott G et al. Tyrosine phosphorylation in human lymphomas. Histochem J 2002; 34: 545–552.

    Article  CAS  Google Scholar 

  45. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708–710.

    Article  CAS  Google Scholar 

  46. Rane SG, Reddy EP . Janus kinases: components of multiple signaling pathways. Oncogene 2000; 19: 5662–5679.

    Article  CAS  Google Scholar 

  47. Morrison JA, Gulley ML, Pathmanathan R, Raab-Traub N . Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res 2004; 64: 5251–5260.

    Article  CAS  Google Scholar 

  48. Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Mills GB, Younes A . Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol 2006; 132: 503–511.

    CAS  Google Scholar 

  49. Vivanco I, Sawyers CL . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489–501.

    Article  CAS  Google Scholar 

  50. Ni Z, Lou W, Lee SO, Dhir R, DeMiguel F, Grandis JR et al. Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma. J Urol 2002; 167: 1859–1862.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Yvonne Blum, Sabine Albrecht, Ekaterini Hadzoglou, Claudia Becher and Dorit Schuster for excellent technical assistance. Supported by grants from the DFG (RK 1315/2-1 and 2-2 to RK and BR 1238/6-1 and 6-2 to AB), the Deutsche Krebshilfe Network (70-3173-Tr3 to MLH, PM and RS) and the Deutsche José Carreras Leukämie Stiftung (to ET).

Author information

Authors and Affiliations

  1. Senckenberg Institute for Pathology, University of Frankfurt, Frankfurt, Germany

    C Renné, K Willenbrock, N Hinsch, C Döring, M-L Hansmann & A Bräuninger

  2. Institute of Human Genetics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

    J I Martin-Subero & R Siebert

  3. Institute for Cell Biology (Tumor Research), University of Duisburg-Essen, Essen, Germany

    E Tiacci & R Küppers

  4. Institute of Pathology, Lymph Node Registry Kiel, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

    W Klapper

  5. Department of Pathology, University of Ulm, Ulm, Germany

    P Möller

Authors
  1. C Renné
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Willenbrock
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J I Martin-Subero
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Hinsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Döring
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E Tiacci
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W Klapper
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Küppers
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M-L Hansmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R Siebert
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A Bräuninger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Bräuninger.

Additional information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Renné, C., Willenbrock, K., Martin-Subero, J. et al. High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. Leukemia 21, 780–787 (2007). https://doi.org/10.1038/sj.leu.2404594

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404594

Keywords

This article is cited by

Search

Advanced search

Quick links